3-Bromopyruvic acid

3-Bromopyruvate (Bromopyruvic acid) is an analogue of pyruvate and a potent hexokinase (HK)-II inhibitor with high tumor selectivity. 3-Bromopyruvate inhibits cell growth and induces apoptosis through interfering with glycolysis. 3-Bromopyruvate induces autophagy by stimulating ROS formation in breast cancer cells. Antimicrobial activities.

Product information

CAS Number: 1113-59-3

Molecular Weight: 166.96

Formula: C3H3BrO3

Synonym:

Bromopyruvic acid

Hexokinase II Inhibitor II

3-BP

Chemical Name: 3-bromo-2-oxopropanoic acid

Smiles: OC(=O)C(=O)CBr

InChiKey: PRRZDZJYSJLDBS-UHFFFAOYSA-N

InChi: InChI=1S/C3H3BrO3/c4-1-2(5)3(6)7/h1H2,(H,6,7)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: H2O : ≥ 32 mg/mL (191.66 mM)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

3-Bromopyruvate enhances TRAIL-induced apoptosis in breast cancer cells. 3-Bromopyruvate (Bromopyruvic acid), a hexokinase II inhibitor, can induce apoptosis in hepatocellular carcinoma cells by inducing endoplasmic reticulum (ER) stress. 3-Bromopyruvate inhibits ATP generation and upregulates the expression of DR5. 3-Bromopyruvate upregulates CHOP, GRP78 and the phosphorylation of AMPK and augments TRAIL-induced Bax and caspase-3 levels.

In Vivo:

3-Bromopyruvate (8 mg/kg; i.p.; every 4 days for 28 days) shows a synergistic antitumor effect in MCF-7 cell xenografts in nude mice.

References:

1. Gan L, et al. Synergistic Effect of 3-Bromopyruvate in Combination with Rapamycin Impacted Neuroblastoma Metabolism by Inhibiting Autophagy. Onco Targets Ther. 2020;13:11125-11137. Published 2020 Oct 29.
2. Chen Y, et al. 3 Bromopyruvate sensitizes human breast cancer cells to TRAIL induced apoptosis via the phosphorylated AMPK mediated upregulation of DR5. Oncol Rep. 2018;40(5):2435-2444.
3. Zhang Q, et al. Hexokinase II inhibitor, 3-BrPA induced autophagy by stimulating ROS formation in human breast cancer cells. Genes Cancer. 2014;5(3-4):100-112.

Products are for research use only. Not for human use.